Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
250mg vs 500mg Fluorescein for Optos Angiography
NCT03244982Phase 4Suspended
- Sponsor
- Kresge Eye Institute
- Start
- Apr 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of fluorescein sodium 10% injection (2 arms), sponsored by Kresge Eye Institute. Primary endpoint: Subjective comparison of image quality between full-dose and half-dose fluorescein angiography performed on the same patient at 6 months. Started Apr 2018; status: suspended.
02
Drugs
fluorescein sodium 10% injection
Beyond the preview
Go deeper on NCT03244982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03244982.